Alberta Investment Management Corp Tcr2 Therapeutics Inc. Transaction History

Alberta Investment Management Corp

  • $10.2 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$2.4 - $4.71 $240,000 - $471,000
-100,000 Closed
0 $0
Q4 2021

Feb 11, 2022
BUY
$4.58 - $8.34 $458,000 - $834,000
100,000 New
100,000 $466,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Alberta Investment Management Corp Portfolio

Follow Alberta Investment Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Alberta Investment Management Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email